Corticosteroid Guidance for Pregnancy during COVID-19 PandemicFunding Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number K08HL150340 (J.J.M.). The content is solely the responsibility of the author and does not necessarily represent the official views of the National Institutes of Health.
28 March 2020
30 March 2020
09 April 2020 (online)
The novel coronavirus disease 2019 (COVID-19) pandemic is causing a necessary, rapid adjustment within the field of obstetrics. Corticosteroid use is a mainstay of therapy for those women delivering prematurely. Unfortunately, corticosteroid use has been associated with worse outcomes in COVID-19 positive patients. Given this information, it is necessary that obstetricians adjust practice to carefully weigh the fetal benefits with maternal risks. Therefore, our institution has examined the risks and benefits and altered our corticosteroid recommendations.
Corticosteroid use is an important part of prematurity treatment because it provides benefit to the fetus.
Corticosteroid use may be related with increased morbidity and mortality in novel coronavirus disease 2019 (COVID-19).
Therefore, during the COVID-19 pandemic, an alteration in current corticosteroid practices is necessary to uniquely weigh the maternal risks and fetal benefits.
- 1 Guan WJ, Ni ZY, Hu Y. , et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
- 2 Shang J, Lu Q, Wu J. , et al. The treatment and outcomes of patients with COVID-19 in Hubei, China: a multi-centered, retrospective, observational study. Lancet 2020 Doi: 10.2139/ssrn.3546060
- 3 Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consens Statement 1994; 12 (02) 1-24
- 4 Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006; (03) CD004454
- 5 Brownfoot FC, Gagliardi DI, Bain E, Middleton P, Crowther CA. Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2013; (08) CD006764
- 6 Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2017; 3: CD004454
- 7 Gyamfi-Bannerman C, Thom EA, Blackwell SC. , et al; NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016; 374 (14) 1311-1320
- 8 Committee on Obstetric Practice. Committee opinion no. 713: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2017; 130 (02) e102-e109
- 9 Obstetric care consensus no. 4: periviable birth. Obstet Gynecol 2016; 127 (06) e157-e169
- 10 Boesveld M, Heida KY, Oudijk MA, Brouwers HA, Koenen SV, Kwee A. Evaluation of antenatal corticosteroid prescribing patterns among 984 women at risk for preterm delivery. J Matern Fetal Neonatal Med 2014; 27 (05) 516-519
- 11 Adams TM, Kinzler WL, Chavez MR, Fazzari MJ, Vintzileos AM. Practice patterns in the timing of antenatal corticosteroids for fetal lung maturity. J Matern Fetal Neonatal Med 2015; 28 (13) 1598-1601
- 12 Travers CP, Clark RH, Spitzer AR, Das A, Garite TJ, Carlo WA. Exposure to any antenatal corticosteroids and outcomes in preterm infants by gestational age: prospective cohort study. BMJ 2017; 356: j1039
- 13 Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ 2012; 345: e6226
- 14 Food and Drug Administration. FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID-19. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19 . Accessed March 20, 2020
- 15 Solaimanzadeh I. Acetazolamide, nifedipine and phosphodiesterase inhibitors: rationale for their utilization as adjunctive countermeasures in the treatment of coronavirus disease 2019 (COVID-19). Cureus 2020; 12 (03) e7343
- 16 Perry Jr. KG, Morrison JC, Rust OA, Sullivan CA, Martin RW, Naef III RW. Incidence of adverse cardiopulmonary effects with low-dose continuous terbutaline infusion. Am J Obstet Gynecol 1995; 173 (04) 1273-1277